v3.26.1
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 12, 2026
USD ($)
Nov. 06, 2025
USD ($)
Nov. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
batch
payment
Mar. 31, 2026
USD ($)
Dec. 31, 2025
USD ($)
Sep. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
batch
payment
Jun. 30, 2025
USD ($)
Jun. 30, 2027
USD ($)
Jun. 30, 2026
USD ($)
payment
Dec. 31, 2025
USD ($)
Subsidiary, Sale of Stock [Line Items]                          
Net cash provided by (used in) operating activities                 $ (20,790) $ (1,079)      
Cash and cash equivalents       $ 24,192   $ 17,973   $ 59 24,192 59   $ 24,192 $ 17,973
Working capital deficit       31,397         31,397     31,397  
Total revenue       15,603       0 26,509 0      
Proceeds from venture loan and security agreement, net                 29,337 0      
Inventory write-off       $ 925         $ 925 0      
Inventory, write-off, number of batches | batch       3         3        
Three Customers | Accounts Receivable | Customer Concentration Risk                          
Subsidiary, Sale of Stock [Line Items]                          
Concentration risk (in percent)                 78.00%       90.00%
Three Customers | Revenue from Contract with Customer Benchmark | Customer Concentration Risk                          
Subsidiary, Sale of Stock [Line Items]                          
Concentration risk (in percent)       82.00%         86.00%        
Customer One | Accounts Receivable | Customer Concentration Risk                          
Subsidiary, Sale of Stock [Line Items]                          
Concentration risk (in percent)                 28.00%       38.00%
Customer One | Revenue from Contract with Customer Benchmark | Customer Concentration Risk                          
Subsidiary, Sale of Stock [Line Items]                          
Concentration risk (in percent)       33.00%         34.00%        
Customer Two | Accounts Receivable | Customer Concentration Risk                          
Subsidiary, Sale of Stock [Line Items]                          
Concentration risk (in percent)                 21.00%       31.00%
Customer Two | Revenue from Contract with Customer Benchmark | Customer Concentration Risk                          
Subsidiary, Sale of Stock [Line Items]                          
Concentration risk (in percent)       21.00%         24.00%        
Customer Three | Accounts Receivable | Customer Concentration Risk                          
Subsidiary, Sale of Stock [Line Items]                          
Concentration risk (in percent)                 29.00%       21.00%
Customer Three | Revenue from Contract with Customer Benchmark | Customer Concentration Risk                          
Subsidiary, Sale of Stock [Line Items]                          
Concentration risk (in percent)       28.00%         28.00%        
Venture Loan And Security Agreement, Term Loans | Line of Credit                          
Subsidiary, Sale of Stock [Line Items]                          
Proceeds from venture loan and security agreement, net                 $ 27,523        
Venture Loan And Security Agreement, Term Loans | Line of Credit | Forecast                          
Subsidiary, Sale of Stock [Line Items]                          
Proceeds from venture loan and security agreement, net                     $ 20    
Convertible Notes | Convertible Debt                          
Subsidiary, Sale of Stock [Line Items]                          
Debt face amount   $ 18,000                      
Convertible notes payable - related party       $ 18,621         18,621     18,621  
Proceeds from convertible note   $ 18,000 $ 17,898                    
Secured Debt | Venture Loan And Security Agreement, Term Loans | Line of Credit                          
Subsidiary, Sale of Stock [Line Items]                          
Proceeds from venture loan and security agreement, net $ 30,000                        
Debt face amount 50,000                        
Remaining borrowing capacity $ 20,000                        
Additional borrowing capacity       10,000         10,000     10,000  
Line of credit facility, remaining borrowing capacity, portion subject to milestone achievement       10,000         10,000     10,000  
Net product revenues                          
Subsidiary, Sale of Stock [Line Items]                          
Total revenue       $ 15,420 $ 10,665 $ 9,094 $ 7,112 $ 0 $ 26,085 $ 0   $ 42,291  
Growth percentage       45.00% 17.00% 28.00%              
Zelsuvmi | Ligand                          
Subsidiary, Sale of Stock [Line Items]                          
Number of milestone payments due | payment       2         2     2  
Accrued milestone payments       $ 10,000         $ 10,000     $ 10,000